Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
Status:
Completed
Trial end date:
1995-02-01
Target enrollment:
Participant gender:
Summary
To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or
AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of
AIDS or ARC. Also, to compare the dose of AZT found to be useful in AIDS and severe ARC with
a lower dose to see if side effects can be reduced.
Results from several studies show that a high percentage of people infected with HIV will
eventually develop AIDS or ARC unless an effective treatment is found. Because AZT is known
to prolong survival in patients with AIDS or severe ARC and has acceptable toxicity in
advanced disease, it is reasonable to try it in less advanced cases.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)